Intriguingly, DCLK1 kinase inhibitor can inhibit DCLK1+ organoids derived from pancreatic ductal adenocarcinoma patient tumors, indicating that DCLK1 activity and perhaps DCLK1+ TCs or acinar cells are a potential target for pancreatic ductal adenocarcinoma [49]. The gene discussed is DCLK1; the disease is pancreatic ductal adenocarcinoma.